[en] The Three-Dimensional Quantitative Structure –Activity Relationship (3D-QSAR) approach using Comparative Molecular Field Analysis (CoMFA) was applied to a series of 39 compounds evaluated as MT3 binding site ligands. The X-ray crystal structure of MT3/quinone reductase 2 was used to obtain the putative bioactive conformation of these ligands. Five statistically significant models were obtained from the randomly constituted training sets (30 compounds) and subsequently validated with the corresponding test sets (nine compounds). The best predictive model (n=30, q2=0.608, N=3, r2=0.897, s=0.288, F=75.4) can predict inhibitory activity for a wide range of compounds and offers important structural insight into designing MT3 ligands prior to their synthesis.
Research center :
Laboratoire de Chimie Thérapeutique, Université de Lille 2 Institut de Recherches Servier
A. B. Lerner, J. D. Case, R. V. Heinzelman, J. Am. Chem. Soc. 1959, 81, 6084.
A. Cagnacci, J. Pineal Res. 1996, 21, 200.
P.-K. Li, P. A. Witt-Enderby, Drugs Future 2000, 25, 945.
A. Miles, D. R. S. Philbrick, C. Thompson, Melatonin, Clinical Perspectives, Oxford University Press, Oxford, 1988.
L. Tamarkin, C. J. Baird, O. F. X. Almeida, Science 1985, 227, 714.
S. M. Reppert, D. R. Weaver, T. Ebisawa, Neuron 1994, 13, 1177.
S. M. Reppert, C. Godson, C. D. Mahle, D. R. Weaver, S. A. Slaugenhaupt, J. F. Gusella, Proc. Natl. Acad. Sci. 1995, 92, 8734.
M. L. Dubocovich, D. P. Cardinali, P. Delagrange, D. N. Krause, A. D. Strosberg, D. Sugden, F. D. Yocca, The IUPHAR Compendium of Receptor Characterisation and Classification, 2 Edn., IUPHAR Media, London, 2000, p. 270.
O. Nosjean, M. Ferro, F. Cogé, P. Beauverger, J.-M. Henlin, F. Lefoulon, J.-L. Fauchère, P. Delagrange, E. Canet, J. A. Boutin, J. Biol. Chem. 2000, 275, 31311.
C. E. Foster, M. A. Bianchet, P. Talalay, M. Faig, L. M. Amzel, Free Radic. Biol. Med. 2000, 29, 241.
C. M. C. Lotufo, C. Lopes, M. L. Dubocovich, S. H. P. Farsky, R. P. Markus, Eur. J. Pharmacol. 2001, 430, 351.
J. Pintor, L. Martin, T. Pelaez, C. H. V. Hoyle, A. Peral, Eur. J. Pharmacol. 2001, 416, 251.
E. J. Molinari, P. North, M. L. Dubocovich, Eur. J. Pharmacol. 1996, 301, 159.
D. S. Pickering, L. P. Niles, Eur. J. Pharmacol. 1990, 175, 71.
R. D. Cramer, III, D. E. Patterson, J. D. Bunce, J. Am. Chem. Soc. 1988, 110, 5959.
P. Gaillard, P.-A. Carrupt, B. Testa, A. Boudon, J. Comp.-Aided Mol. Design 1994, 8, 83.
B. Testa, P.-A. Carrupt, P. Gaillard, F. Billois, P. Weber, Pharm. Res. 1996, 13, 335.
C. E. Foster, M. A. Bianchet, P. Talalay, Q. Zhiao, L. M. Amzel, Biochemistry 1999, 38, 9881.
V. Leclerc, S. Yous, P. Delagrange, J. A. Boutin, P. Renard, D. Lesieur, J. Med. Chem. 2002, 45, 1853.
T. I. Oprea, C. L. Waller, G. R. Marshall, J. Med. Chem. 1994, 37, 2206.
SYBYL, 6.9.1 ed., Tripos Associates Inc., 1699 South Hanley Road, St. Louis, MO 63144.
M. Clark, R. D. Cramer, III, N. Van Opdenbosch, J. Comput. Chem. 1989, 10, 982.
G. Jones, P. Willet, R. C. Glen, A. R. Leach, R. Taylor, J. Mol. Biol. 1997, 267, 727.
R. Wang, L. Lai, S. Wang, J. Comp.-Aided Mol. Design 2002, 16, 11.
J. J. P. Stewart, J. Comp.-Aided Mol. Design 1990, 4, 1.
M. Clark, R. D. Cramer, III, Quant. Struct.-Act. Relat. 1993, 12, 137.
S. S. Kulkarni, V. M. Kulkarni, J. Med. Chem. 1999, 42, 373.
